The therapeutic efficacy of Chinese patent medicine combined with routine western medicine in the treatment of coronavirus disease 2019 (COVID-19)

Abstract

Background: Coronavirus disease 2019 (COVID-19) is a potentially fatal disease. clinical practice shows that Chinese Patent Medicine (CPM) has played an important role in the outbreak, Among them, Jinhua Qinggan granules, Lianhua Qingwen capsule, and Xuebiqing injection have an effect in treating COVID-19 patients, but it has not been systematically evaluated for efficacy and safety. We provide a protocol for systematic review and meta-analysis. Materials and methods: Retrieved the database, including the China National Knowledge Infrastructure, Chinese Biomedical Database, Wan Fang database, and PubMed. The quality of each study is assessed according to the criteria of the Cochrane Handbook for Systematic Reviews of Interventions. Using Manager 5.3 software and STATA 16.0 software were used to perform the meta-analysis. Results: The systematic review and meta-analysis aims to review and pool current clinical outcomes of CPM combined with routine western medicine (RWM) for the treatment of COVID-19. Conclusion: This study will provide evidence of CPM (including Jinhua Qinggan granule, Lianhua Qingwen capsule, and Xuebiqing injection) for the treatment on COVID-19 patients. INPLASY Registration number: INPLASY202050050.

Chinese patent medicine for functional dyspepsia effects

“…It is a commercialized preparation approved by the China Food and Drug Administration. [15,16] Since an increasing number of Chinese patent medicines in treating FD appeared, making clinical application a difficult decision as it remains inconclusive which Chinese patent medicine can obtain the greatest benefits. Therefore, we decide to rank the efficacy of these 9 Chinese patent medicines by network meta-analysis.…”

“…Chinese patent medicine as a type of TCM product uses herbal medicine as raw material and is processed into certain dosage forms according to the prescribed prescription. It is a commercialized preparation approved by the China Food and Drug Administration [15,16] . Since an increasing number of Chinese patent medicines in treating FD appeared, making clinical application a difficult decision as it remains inconclusive which Chinese patent medicine can obtain the greatest benefits.…”

Clinical efficacy and safety of Qingshu Yiqi decoction as a complementary and alternative therapy for COVID-19 with Delta variant

“…In clinical application, the key points of syndrome differentiation are fever and sweating, thirst and upset, fatigue and weak breath, and the pulse is feeble and rapid. Preliminary research shows that western medicine combined with traditional Chinese medicine has a certain effect on COVID-19 and has achieved certain results [20–22] . However, due to the limitations of the study and the small sample size, it has certain limitations in guiding the clinical application of Qingshu Yiqi decoction combined with general western medicine in the treatment of COVID-19 with Delta variant.…”

“…Preliminary research shows that western medicine combined with traditional Chinese medicine has a certain effect on COVID-19 and has achieved certain results. [20][21][22] However, due to the limitations of the study and the small sample size, it has certain limitations in guiding the clinical application of Qingshu Yiqi decoction combined with general western medicine in the treatment of COVID-19 with Delta variant. Therefore, this current meta-analysis aims to systematically evaluate and analyze its clinical efficacy and safety, so as to provide evidence-based medical reference for COVID-19 with Delta variant.…”